Bos et al(30) investigated the expression levels of HIF-1α, HER-2/neu, estrogen receptor and progesterone receptor in 150 patients with early-stage breast carcinoma using immunohistochemistry and HER-2/neu gene amplification with automated fluorescent in situ hybridization. Here, ERBB2 is linked to breast carcinoma.